This is a first-in-human, Phase 1/2 open-label, multi-center, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.~This study is being conducted in three parts:~Part A: Phase 1 Monotherapy Dose Escalation (SNS-101 alone)~Part B: Phase 1 Combination Dose Escalation (SNS-101 in combination with cemiplimab)~Part C: Phase 2 Expansion Cohorts (SNS-101 alone or in combination with cemiplimab)
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.